Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
about
A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Extended-release niacin acutely suppresses postprandial triglyceridemia.High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes.Niacin for primary and secondary prevention of cardiovascular events.Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS studyNiacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease.Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Novel metabolic biomarkers of cardiovascular disease.New and emerging biomarkers in cardiovascular disease.Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation.Elevated serum lipoprotein(a) as a risk factor for combined intracranial and extracranial artery stenosis in a child with arterial ischemic stroke: A case report.Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression.Pharmacokinetics of Single-Dose and Multi-Dose of Lovastatin/Niacin ER Tablet in Healthy Volunteers
P2860
Q33765072-2FFE3C5B-5EC2-4AEE-9155-EDAD9F89085FQ34223452-3745618C-29A0-48BB-A8B9-6DEBE24AE5CBQ34297896-F75CD86F-0F78-4D8C-B4F7-41D739BCF526Q34682221-005B4608-ED63-4D85-9079-1AD1C8577B5FQ35737842-AFF9FE99-9A2C-46C4-8B6A-4B81761FA9E0Q36536280-F38E3CDB-D99C-4059-B069-7DF9B61265E1Q36540320-4D19F56D-745A-4B8D-BA52-449AB93E2C8BQ36650095-A4AA11E9-A80B-4144-8EEA-88EF3B2A5A9DQ36772880-D63C48F1-642E-4738-B830-681849C7D00AQ36968971-C43FBB25-C96A-408F-ACD9-5C6C64E640B8Q37329136-1BFF0DB5-96A9-4A67-B4A9-9AEDEC11CEF7Q38011204-3C74CD7A-935E-48F4-A40F-D141E6E2575FQ38245327-395B5B60-7B7D-4200-BCF3-B9D4BF9DCB00Q38586900-D5E19833-3CC7-461D-89F5-3044DCBE24CDQ38765419-C6F2AB97-C612-4F09-91BD-2014BDE69E4FQ47098191-FAF7E97D-FA10-4E05-8CDC-42BDD082C6F4Q51833326-24E3A4A2-26A8-4AB0-A149-E0766B84766EQ58700068-CA6C8131-140A-4134-8404-CF70B90A01B4
P2860
Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Efficacy of extended-release n ...... vative surface graph analysis.
@en
Efficacy of extended-release n ...... vative surface graph analysis.
@nl
type
label
Efficacy of extended-release n ...... vative surface graph analysis.
@en
Efficacy of extended-release n ...... vative surface graph analysis.
@nl
prefLabel
Efficacy of extended-release n ...... vative surface graph analysis.
@en
Efficacy of extended-release n ...... vative surface graph analysis.
@nl
P2093
P1476
Efficacy of extended-release n ...... vative surface graph analysis.
@en
P2093
Franklin Zieve
Helmut Schrott
J Robin Crouse
John Corbelli
Mark E McGovern
Paul Thompson
William Insull
P304
P356
10.1001/ARCHINTE.164.10.1121
P407
P577
2004-05-01T00:00:00Z